Lisata Therapeutics sues Kuva Labs over breached merger agreement, seeks $2 million fee
LSTA•Lawsuit over merger agreement
Lisata Therapeutics filed suit in Delaware Chancery Court against Kuva Labs over an alleged breach of the March 6, 2026 merger agreement.
The complaint seeks damages for stockholders, including a USD 2 million termination fee under the merger agreement.
The litigation follows termination of the merger agreement with Kuva Labs and its Kuva Acquisition unit.
